TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
4.550
-0.060 (-1.30%)
May 6, 2026, 3:16 PM EDT - Market open
TriSalus Life Sciences Employees
TriSalus Life Sciences had 102 employees as of December 31, 2025. The number of employees decreased by 8 or -7.27% compared to the previous year.
Employees
102
Change (1Y)
-8
Growth (1Y)
-7.27%
Revenue / Employee
$442,657
Profits / Employee
-$683,235
Market Cap
279.44M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 102 | -8 | -7.27% |
| Dec 31, 2024 | 110 | -2 | -1.79% |
| Dec 31, 2023 | 112 | 37 | 49.33% |
| Dec 31, 2022 | 75 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| InfuSystem Holdings | 473 |
| RxSight | 461 |
| CVRx, Inc. | 223 |
| Sight Sciences | 186 |
| Electromed | 180 |
| 908 Devices | 172 |
| ClearPoint Neuro | 172 |
| Profound Medical | 162 |
TLSI News
- 1 day ago - TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors - Business Wire
- 7 days ago - TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call - Business Wire
- 26 days ago - TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting - Business Wire
- 4 weeks ago - TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer - Business Wire
- 7 weeks ago - TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models - Business Wire
- 2 months ago - TriSalus Life Sciences Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance - Business Wire
- 2 months ago - TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call - Business Wire